Interventional psychiatry is a specialized branch that uses advanced technology and targeted medical procedures to directly revitalize the neural pathways responsible for mood and cognition. It’s often the next step when traditional antidepressants aren’t providing enough relief or when side effects become a barrier to recovery. 

While both TMS and Spravato are advanced tools for treatment-resistant depression, they operate through different biological mechanisms and offer unique paths to recovery. TMS is a non-invasive, drug-free procedure that uses magnetic fields to physically stimulate neural activity. Its long-term benefit lies in structural neuroplasticity, where the brain actually grows new connections over several weeks to build a lasting foundation for mood regulation. By contrast, Spravato is a novel medication that works through a distinct neurochemical pathway that helps stimulate the brain’s mood centers. 

Choosing between them—or using them in tandem—depends on your clinical needs: TMS offers a durable, structural reboot that can provide years of relief, while Spravato acts as a fast-acting catalyst to restore immediate function and clarity. 

The goal of traditional treatments like talk therapy or medication is steady progress, so relief is more gradual. As it takes time for medication to build in your system and for therapeutic insights to translate into lifestyle changes, people usually feel better in 4 to 12 weeks.  

In contrast, TMS and Spravato are designed to “jumpstart” the brain and provide accelerated momentum. With Spravato, many patients feel an initial lift in mood and clarity within the first few sessions. With TMS, the brain is physically building new connections and relief is slightly more gradual, with most patients noticing a change around the third week. In both cases, the goal is not just the absence of depression, but the restoration of positive function, energy, and mental sharpness. 

Traditional antidepressants attempt to balance brain chemistry by increasing the availability of certain neurotransmitters. Interventional procedures like TMS go a step further. They provide a physical stimulus that encourages synaptogenesis—the actual growth and strengthening of the neural branches (dendrites) that allow your brain to communicate effectively. 

Yes, both TMS and Spravato are FDA-approved for treatment-resistant depression and covered by Medicare and most insurance plans for treatment-resistant depression. Our team handles the pre-authorization process so you have clarity on your coverage before you begin. 

Our co-founders have practiced interventional psychiatry for over 20 years, setting the standard of excellence for TMS in Southern California and beyond. All Headlight clinicians—therapists, nurse practitioners, and psychiatrists—work in a shared ecosystem that allows for seamless collaboration. This integrated environment ensures that you receive the care you need when you need it.

Better yet, it’s faster. By offering a full spectrum of treatments, we provide the quickest path to remission of your symptoms. Our clinicians are credentialed and rigorously screened to deliver the highest standard of care while adhering to all FDA protocols. They can consult each other directly, monitor your mood and success during the course of treatment, and make real-time, highly personalized adjustments.  

Headlight offers a free consultation, then a clinical pre-assessment. The consultation is a great time to ask questions and learn more about the treatments. During the pre-assessment, the Headlight team will review your medical history and past treatment trials to determine which interventional path makes the most sense for your biology. 

If you’re already a Headlight patient, you can speak directly with your current therapist or psychiatrist to initiate a screening, as our team works collaboratively on a single health record. You can also call us 858-866-9454 or fill out an intake form at any time.